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The Journal of Immunology
Activating Transcription Factor 3 Is a Positive Regulator of
Human IFNG Gene Expression
Sanna File´n,*,† Emmi Ylikoski,*,‡ Subhash Tripathi,* Anne West,* Mari Bjo¨rkman,*
Joel Nystro¨m,* Helena Ahlfors,*,x Eleanor Coffey,* Kanury V. S. Rao,{ Omid Rasool,*
and Riitta Lahesmaa*,‖
IL-12 and IL-18 are essential for Th1 differentiation, whereas the role of IFN-a in Th1 development is less understood. In this
microarray-based study, we searched for genes that are regulated by IFN-a, IL-12, or the combination of IL-12 plus IL-18 during
the early differentiation of human umbilical cord blood CD4+ Th cells. Twenty-six genes were similarly regulated in response to
treatment with IL-12, IFN-a, or the combination of IL-12 plus IL-18. These genes could therefore play a role in Th1 lineage
decision. Transcription factor activating transcription factor (ATF) 3 was upregulated by these cytokines and selected for further
study. Ectopic expression of ATF3 in CD4+ T cells enhanced the production of IFN-g, the hallmark cytokine of Th1 cells, whereas
small interfering RNA knockdown of ATF3 reduced IFN-g production. Furthermore, ATF3 formed an endogenous complex with
JUN in CD4+ T cells induced to Th1. Chromatin immunoprecipitation and luciferase reporter assays showed that both ATF3 and
JUN are recruited to and transactivate the IFNG promoter during early Th1 differentiation. Collectively, these data indicate that
ATF3 promotes human Th1 differentiation. The Journal of Immunology, 2010, 184: 4990–4999.
N
aive CD4+ Th lymphocytes are capable of differentiating
into functionally distinct subsets. These include IFN-g,
IL-2, and TNF-b–secreting Th1 cells, IL-4, IL-5, and IL-
13–secreting Th2 cells (1), IL-17, IL-17F, IL-21, IL-22, and TNF-
secreting Th17 cells, (2–6), and naturally occurring CD4+CD25+
Foxp3+ T regulatory cells (7–11). The differentiation process is
initiated by Ag encounter (i.e., activation via TCR/CD28) and
controlled by the cytokine environment (reviewed in Ref. 12). IL-
12R–mediated STAT4 signaling is the key event in Th1 lineage
commitment, as shown by the studies using knockout mice de-
ficient for IL-12 (13), IL-12Rb2 (14), or Stat4 (15), which all ex-
hibit impaired Th1 responses and reduced IFN-g production. IL-18
is a cytokine that is also intrinsically involved in Th1 differentia-
tion. It synergizes with IL-12 in the induction of IFN-g, although it
is unable to drive Th1 polarization on its own (16).
The precise role of type I IFNs in STAT4-dependent Th1 differ-
entiation and IFN-g production has yet to be resolved. Initially, it
was shown by Brinkmann et al. (17) that human CD4+ T cells
produce increased levels of IFN-g in the presence of IFN-a, which
suggests that type I IFNs favor Th1 differentiation. Later, IFN-a/b
in synergy with IL-18 was reported to induce IFN-g production by
T cell blasts (18). Furthermore, in the same report, IFN-awas shown
to increase IFNG mRNA synthesis in human T cells. There is also
clear evidence that type I IFNs are able to tyrosine phosphorylate
and activate STAT4 in primary human T cells (19, 20). However, the
ability of IFN-a to optimally drive the invitro polarization of human
Th1 cells has been called into question (21). Although IL-12 in-
duced sustained phosphorylation of STAT4, the response to IFN-a
was only transient and not sufficient for efficient Th1 polarization.
We hypothesized that genes regulated by several Th1-inducing
cytokines are likely to be important for Th1 differentiation. To study
this, we profiled the cytokine-induced (IFN-a, IL-12, or the com-
bination of IL-12 plus IL-18) gene expression during the early stages
of human umbilical cord blood CD4+ T cell differentiation. Oligo-
nucleotide microarrays with probes for ∼22,000 genes were used.
This resulted in the identification of 26 genes with a similar ex-
pression pattern in response to the studied cytokines. Several of the
genes identified have not been previously associated with Th1 dif-
ferentiation, although the expected regulation of known marker
genes was also observed. Activating transcription factor (ATF) 3
was upregulated by all the cytokines studied. It is a member of the
ATF/CREB family of transcription factors, and its functional role in
human Th cell differentiation has not previously been addressed. In
this report, we show that in Th1-promoting conditions, ATF3 pos-
itively regulated IFNG gene expression and Th1 differentiation.
Materials and Methods
Primary CD4+ T cell isolation and culture
Lymphocytes were isolated from heparinized human umbilical cord blood
samples (Turku University Hospital, Turku, Finland) or from buffy coats
from healthy blood donors (Red Cross Finland Blood Service, Helsinki,
Finland) by Ficoll-Paque gradient centrifugation (Amersham Pharmacia
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Biotech, Uppsala, Sweden). CD4+ T cell enrichment was performed using
anti-CD4–conjugated magnetic beads (Dynal, Oslo, Norway). Cells were
cultured in Yssel’s medium (22) supplemented with 1% human AB serum
(Red Cross Finland Blood Service). Cells were activated with either plate-
bound anti-CD3 (2.5 mg/ml for coating) and 0.5 mg/ml soluble anti-CD28
(Immunotech, Marseille, France) or with 100 ng/ml PHA (Murex Diag-
nostics, Chatillon, France) and irradiated CD32/B7 transfected mouse L
fibroblasts. A total of 2.5 ng/ml IL-12 (R&D Systems, Minneapolis, MN),
25 ng/ml IL-18 (Medical & Biological Laboratories, Nagoya, Japan), and
100 U/ml highly purified human leukocyte IFN-a (Red Cross Finland
Blood Service) were used to induce Th1 polarization and 10 ng/ml IL-4
(R&D Systems) to promote Th2 differentiation. For neutral Th0 con-
ditions, no polarizing cytokines were added. Where indicated, 3 mg/ml
neutralizing anti–IFN-g (clone 25718, R&D Systems) was added to the
culture media. To promote proliferation, 17 ng/ml IL-2 (R&D Systems)
was added on the second day of culture to 7-d cultures.
Microarray studies
Cells were harvested at different time points and lyzed in TRIzol Reagent
(Invitrogen, Carlsbad, CA). Total RNAwas further purified using an RNeasy
minikit (Qiagen, Valencia, CA). Sample preparation for GeneChip oligo-
nucleotide array hybridizations was performed according to Affymetrix’s
instructions using 5 mg total RNA as starting material. Samples were
hybridized to HG-U133A arrays (Affymetrix, Santa Clara, CA). Micro-
array Suite 5.1 software (Affymetrix) was used for data analysis. Data was
normalized using the global normalization method and the expression
analysis settings predefined by the manufacturer. Changes in gene ex-
pression levels between two samples were considered significant if 21 $
signal log2 ratio (SLR) $ 1, which equals a 2-fold change.
Quantitative real-time RT-PCR (TaqMan)
Total RNAwas isolated from cells cultured in polarizing conditions with an
RNeasyMini Kit (Qiagen), and cDNA synthesis was performed from 0.5mg
DNase I treated total RNA using SuperScript II (Invitrogen). The primer
and probe sequences used in TaqMan analysis were as follows: pIFNG-
fwd: 59-ctcgaaacagcatctgactcctt-39; pIFNG-rev: 59-tgtccaacgcaaagcaataca-
39; probe-IFNG: 59-(FAM)-tgctggcgacagttcagccatcac-(TAMRA)-39; pEE-
F1A1-fwd: 59-ctgaaccatccaggccaaat-39; pEEF1A1-rev: 59-gccgtgtggcaatc-
caat-39; and probe-EEF1A1: 59-(FAM)-agcgccggctatgcccctg-(TAMRA)-
39. TaqMan analyses were performed with an ABI Prism 7700 Sequence
Detector (Applied Biosystems, Foster City, CA) as described earlier (23).
All analyses were performed in duplicate in two separate runs using
samples from at least three cultures. Housekeeping gene EEF1A1 was used
as a reference for normalization (24).
Western blotting
Cells were lyzed in SDS sample buffer (62 mM Tris-HCl [pH 6.8], 2% w/v
SDS, 10% v/v glycerol, 50 mM DTT, and 0.1% w/v bromphenol blue), and
proteins were separated by SDS-PAGE by a standard Laemmli method (25).
The separated proteins were transferred to nitrocellulose membranes (Hy-
bond ECL, Amersham Biosciences, Buckinghamshire, U.K.) and blocked
with 5%nonfat driedmilk and 0.1%Tween20/TBS.AllAb incubationswere
performed in blocking solution, and the following Abs/antiserumwere used:
1:1000 anti-ATF3 (rabbit IgG, C-19; Santa Cruz Biotechnology, Santa Cruz,
CA), 1:800 anti-JUN (mouse IgG2a, clone 3; BD Biosciences, Franklin
Lakes, NJ), 1:7500 goat anti-rabbit Ig-HRP (BD Biosciences). and 1:10,000
goat anti-mouse IgG-HRP (Santa Cruz Biotechnology). The ECL detection
system (Amersham Biosciences) was used for visualization of proteins.
b-actin was blotted to control for equal loading with 1:10,000 anti–b-actin
(AC-15; Sigma-Aldrich, St. Louis, MO).
Plasmid constructs and small interfering RNA oligonucleotides
ATF3 was cloned into pcDNA3.2/V5/GW/D-TOPO vector (Invitrogen)
according to the manufacturer’s instructions using PCR primers pATF3-
fwd: 59-caccatgatgcttcaacacc-39 and pATF3-rev: 59-ttagctctgcaatgttccttc-39
and cDNA prepared from total RNA isolated from human T cells as
template. The Gateway Vector Conversion System (Invitrogen) was used to
modify pIRES2-H-2Kk vector (26) into Gateway destination vector
pIRES2-GW-H-2Kk. ATF3 was subcloned from pcDNA3.2 vector into
pIRES2-GW-H-2Kk via pDONR/Zeo vector (Invitrogen) generating vector
pATF3-IRES2-H-2Kk. PCR primers pJUN-fwd-EcoRI: 59-atcgaattcatga-
ctgcaaagatggaaacgac-39 and pJUN-rev-BamHI: 59-atcggatcctcaaaatgtttg-
caactgctgcg-39 were used to directly clone JUN into EcoRI-BamHI–
digested pIRES2-H-2Kk to create plasmid pJUN-IRES2-H-2Kk.
Cloning of IFNG promoter constructs illustrated in Fig. 7Awas started by
amplifying a 1.25-kb fragment from human IFNG promoter with primers
IFNG_fwd: 59-atgtgcccattaagcgtttg-39 and IFNG_rev: 59-agctgatcaggtc-
caaagga-39 using human gDNA as template. Nested sets of primers were
used to clone IFNG promoter fragments of differing length to KpnI-HindIII–
digested pGL4.10[luc2] vector (Promega, Madison, WI). The sequences of
the nested primers were: IFNG_1147_f: 59-atatggtaccgaccaaattgagatgcac-
39; IFNG_940_f: 59-atatggtacctacaccaccatgcctg-39; IFNG_730_f: 59-atatg-
gtaccatgtcaaataccttattaac-39; IFNG_510_f: 59-atatggtaccttactaaccaactctgat-
39; IFNG_292_f: 59-atatggtaccgggaggtacaaaaaaattt-39; IFNG_+38_r: 59-
atataagcttcttctaatagctgatcttca-39; IFNG_1147_as: 59-atataagcttgaccaaattga-
gatgcac-39; and IFNG_+38_as: 59-atatggtacccttctaatagctgatctt-39. Deletion
mutations of the potential ATF3/JUN binding sites were generated on
pIFNG1147-GL4.10 using Phusion Site-Directed Mutagenesis Kit (Finn-
zymes, Espoo, Finland). The primers used for the generation of themutations
were: IFNG_del1_f: 59-cctccctagtagctgagattacaggca-39; IFNG_del1_r: 59-
agaatggcttgaacccagaaggtg-39; IFNG_del2_f: 59-attttaccagggcgaagtggggag-
39; IFNG_del2_r: 59-tcattcacaaagcacattgatcatttgc-39; IFNG_del3_f: 59-cgt-
caaaggacccaaggagtctaaagg-39; IFNG_del3_r: 59-cattatgcccacctgtgccattct-
39; IFNG_del4_f: 59-cctcaggagacttcaattaggtataaatacc-39; IFNG_del4_r:
59-tcacaagttttttaagatgagatggtg-39; IFNG_del5_f: 59-agtgccttcaaagaatcccac-
cag-39; and IFNG_del5_r: 59-caccattcaaggactggaaatttttttg-39.
Small interfering RNA (siRNA) oligonucleotides targeting ATF3 (ATF3-
siRNA3: 59-cauuugauauacaugcucatt-39; ATF3-siRNA4: 59-gaaaccu-
cuuuauccaacatt-39; and ATF3-siRNA-new2: 59-gaaggaacauugcagagcu-39)
and control (scramble-siRNA1: 59-gcgcgcuuuguaggauucguu-39) (all from
Sigma/Proligo, Evry Cedex, France) were used in knockdown studies.
Nucleofection, dead cell removal, and enrichment of
transfected cells
The protocol for nucleofection, dead cell removal, and enrichment of
transfected cells is described elsewhere (26). Briefly, 5 mg plasmids pATF3-
IRES2-H-2Kk and empty vector pIRES2-H-2Kk or 1.5 mg oligonucleotide
siRNAs targeting ATF3 or control (scramble) were used per 4 to 5 3 106
cells suspended in 100 ml Opti-MEM I (Invitrogen). Postnucleofection, the
cells were let to rest 20 h in RPMI 1640 supplemented with 10% FBS,
penicillin plus streptomycin, and 2 mM L-glutamine. When the cells were
nucleofected with plasmid DNA, a Dead Cell removal kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) and anti-H-2Kk–coated magnetic beads
(Miltenyi Biotec) were used to remove dead cells and enrich the trans-
fected cells. Cells transfected with oligonucleotide siRNAs were not sor-
ted. In vitro Th1 differentiation of the transfected cells was performed by
using anti-CD3/anti-CD28 activation and IL-12 as a polarizing cytokine as
described above.
Jurkat cell transfections
Jurkat E6-1 or Jtag cell lines were maintained in RPMI 1640 supplemented
with 10% FCS, penicillin/streptomycin, and 2 mM L-glutamine. A total of
5 3 106 cells were transfected by electroporation with 5–15 mg plasmid
DNA, and the cells were rested overnight (o/n). The next day, the cells
were activated with 50 ng/ml PMA (Calbiochem, San Diego, CA) and
1 mg/ml PHA (Sigma-Aldrich). When the effect of ATF3/JUN over-
expression on IFNG gene transcription was studied, the cells were har-
vested after 24 h of activation and H-2Kk–positive cells were sorted using
magnetic beads as described elsewhere (26). Cells used in transactivation
assays were not H-2Kk selected.
Flow cytometric analysis of intracellular cytokines
Sample preparation for flow cytometric analysis of intracellular cytokine
staining was performed as previously described (26). Briefly, cells harvested
7 d after culture were stimulated with 5 ng/ml PMA (Calbiochem) and 0.5
pg/ml ionomycin (Sigma-Aldrich) in Yssel’s medium. A portion of the cells
was incubated in Yssel’s medium only and used as an unstimulated control.
After 2 h of stimulation, 10 mg/ml brefeldin A (Alexis Biochemicals,
Lausanne, Switzerland) was added to all samples, and incubation was
continued for 3 h. Cells were washed and fixed with 4% (w/v) para-
formaldehyde/PBS and permeabilized with 0.5% (w/v) saponin/PBS. Anti-
human–IFN-g-FITC (B27; Caltag Laboratories, Burlingame, CA) was used
for staining of the intracellular IFN-g, and mouse IgG1-FITC (Caltag
Laboratories) was used as an isotypic control. Cells were analyzed with an
FACSCalibur Flow Cytometer (BD Biosciences).
IFN-g cytokine assay
Human umbilical cord blood CD4+ T cells that were nucleofected with
siRNA oligonucleotides were induced toward Th1 as described above.
Supernatants were collected after 24 h of culture for analysis of IFN-g
production. After 7 d of stimulation, the cells were treated with 5 ng/ml
PMA and 0.5 pg/ml ionomycin for 24 h and the supernatants collected. A
The Journal of Immunology 4991
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Bio-Plex Cytokine Assay kit (Bio-Rad, Hercules, CA) was used for IFN-g
detection according to the manufacturer’s instructions, and the assays were
analyzed with Luminex 100 IS 2.2 (Luminex, Austin, TX).
Nuclear extracts and ATF3/JUN coimmunoprecipitations
Human umbilical cord blood CD4+ T cells were isolated, activated with
anti-CD3 and anti-CD28, and cultured in the presence or absence of IL-12
or IL-4 or in the absence of cytokines as described above. Cells were
harvested after 48 h, and nuclear extracts were prepared as described be-
low. The cells were washed twice with PBS and lyzed in 250 ml lysis
buffer (21.8 mM HEPES [pH 7.9], 0.2% Tween-20, 1 mM NaF, 1 mM
Na3VO3, 1 mM DTT, 1 mM PMSF, and protease inhibitor Complete Mini
[Roche, Basel, Switzerland]). After 2 min incubation, cells were centri-
fuged, and cytoplasmic fractions were collected. A total of 100 ml nuclear
lysis buffer (21.8 mM HEPES (pH 7.9), 430 mM NaCl, 1% glycerol, 1 mM
NaF, 1 mM Na3VO3, 1 mM DTT, 1 mM PMSF, and protease inhibitor
Complete Mini [Roche]) was added, and the samples were incubated on
ice for 1 h. Thereafter, the samples were sonicated, centrifuged, and the
soluble fractions collected. Nuclear extracts were precleared with 100 ml
protein G-Sepharose 4 Fast Flow beads (Amersham Biosciences) for 2 h at
4˚C. The samples were spun, and supernatants were collected. A total of
1.5 mg anti-ATF3 Ab and 10 ml JUN antiserum (polyclonal anti-JUN was
raised in rabbits inoculated with rGST-human-JUN [5–89 aa]) were used
for immunoprecipitation; 1.5 mg anti-RANKL Ab (rabbit IgG, FL-317;
Santa Cruz Biotechnology) was used as control. Ab incubations were done
o/n at 4˚C. A total of 50 ml protein G-Sepharose beads were added for
collecting the protein-Ab complexes, and the samples were incubated 1 h
at 4˚C. The beads were washed three times in 1 ml PBS, and 20 ml SDS
sample buffer was added for eluting the proteins in 95˚C for 5 min.
Chromatin immunoprecipitation assay
Freshly isolated human umbilical cord blood CD4+ T cells were induced
toward Th1 and Th2 as described above. Poststimulation, the protein-DNA
complexes were cross-linked with 1/10 volume of cross-linking solution
(50 mM HEPES-KOH [pH 7.5], 100 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, and 11% formaldehyde) for 10 min and quenched with 1/20 vol-
ume of 2.5 mM glycine solution for 10 min, after which the cells were
washed twice with ice-cold PBS. The cells were pelleted, and nuclear
fractions were prepared. The cell pellet was resuspended in 30 ml lysis
buffer 1 (50 mM HEPES KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA,
10% glycerol, 0.5% Nonidet P-40, and 0.25% Triton X-100 with protease
inhibitor Complete Mini [Roche]) and mixed for 10 min at 4˚C. Post-
centrifugation at 2000 3 g for 10 min at 4˚C, the cell pellet was re-
suspended in 24 ml lysis buffer 2 (200 mM NaCl, 1 mM EDTA [pH 8],
0.5 mM EGTA, and 10 mM Tris [pH 8], with protease inhibitor) at room
temperature for 10 min. Postcentrifugation at 2000 3 g for 10 min at 4˚C,
the pellet was resuspended in 10 ml lysis buffer 3 (1 mM EDTA [pH 8],
0.5 mM EGTA [pH 8], and 10 mM Tris [pH 8], with protease inhibitor).
The chromatin was sheared by sonication, and the fragmentation was ana-
lyzed with agarose gel electrophoresis. The majority of the DNA fragments
were in the 400–1000 bp range. Cell debris was removed by centrifugation at
10,000 3 g for 10 min, and the supernatant was collected for chromatin
immunoprecipitation (ChIP). A total of 20 ml chromatin supernatant was
retained as the DNA input control in the following PCR reaction.
Magnetic beads were used for ChIP, and 50 ml sheep anti-rabbit IgG-
conjugated Dynabeads (Dynal) were conjugated with 10 mg anti-ATF3 (C-
19; Santa Cruz Biotechnology), 10 ml polyclonal anti-JUN, or 5 mg control
rabbit IgG (sc-2027; Santa Cruz Biotechnology) in PBS containing 5 mg/ml
BSA o/n at 4˚C. Beads were collected by centrifugation, washed three times
with PBS/BSA, and resuspended in 100 ml PBS/BSA for immunoprecipi-
tation. Equal volumes of soluble chromatin were divided into sample and
control and adjusted to 0.1% Triton X-100, 0.1% sodium deoxycholate, and
1 mM PMSF, mixed with 100 ml magnetic beads prebound to the Ab and
incubated at 4˚Co/n. Themagnetic beadswere collected, and the supernatant
was removed. To remove nonspecifically bound material, the beads were
resuspended to 1 ml RIPA buffer (50 mM HEPES [pH 7.6], 1 mM EDTA,
0.7% sodium deoxycholate, 1%Nonidet P-40, and 0.5MLiCl, with protease
inhibitor mixture) at 4˚C. The beads were collected and washed with RIPA
buffer a total of 10 times. After washing once with 1 ml TE buffer, the beads
were collected by centrifugation at 2000 3 g for 3 min and resuspended in
50 ml elution buffer (50 mM Tris [pH 8], 10 mM EDTA, and 1% SDS). To
elute precipitated chromatin from the beads, the tubes were incubated at 65˚
for 30 min with constant agitation and centrifuged for 1 min at 20003 g. A
total of 40 ml eluted supernatants were removed and mixed with 120 ml TE
buffer. Similarly, 20 ml chromatin input control was mixed with 140 ml TE
buffer. Cross-links were reversed by incubation at 65˚C o/n.
Proteins in the DNA sample were removed by incubation with 120 ml
proteinase K solution (2% glycogen, 5% proteinase K stock solution, and
TE) for 2 h at 37˚C. The DNA was then extracted twice with phenol and
once with 24:1 chloroform/isoamyl alcohol. The sample was adjusted to
200 mM NaCl. After ethanol precipitation, the DNAwas dissolved in 30 ml
TE containing 10 mg DNase-free RNase A and incubated for 2 h at 37˚C.
The DNA was further purified with a Qiagen PCR kit (Qiagen). Primers
F1: 59-cttgcagtgagccgagattg-39, R1: 59-ccagcctaggtgacagagtaagat-39, F2:
59-gaccaaattgagatgcaccgtagg-39, R2: 59-cacttcgccctggtaaaatgtt-39, F3: 59-
cattctttccttgctttctggtc-39, and R3: 59-tgcttcttttacatatgggtcctg-39 were used
for PCR amplification.
Transactivation assays
Jurkat Jtag cells (27) were used in transactivation assays, and they were
transfected as described above. IFNG promoter constructs were co-
transfected with either pATF3-IRES2-H-2Kk or pJUN-IRES2-H-2Kk
plasmids alone or with both. A total amount of 15 mg plasmid DNA/5 3
106 cells was used in transfections. The values of luciferase assays of the
mutation analysis were normalized by the transfection efficiency values
(i.e., the percentage of H-2Kk–positive cells). Britelite plus (PerkinElmer,
Waltham, MA) was used to measure luciferase activity, and the results
were read with a Victor 1420 Multilabel Counter (PerkinElmer).
Prediction of ATF3/JUN binding sites
Putative ATF3/JUN binding sites in the human IFNG promoter (21147 to
+38) were analyzed with both MatInspector (Genomatix Software, Mu-
nich, Germany) and AliBaba 2.1 (Biobase, Wolfenbuettel, Germany).
Accession numbers
The Affymetrix gene expression data were deposited to the NCBI Gene
Expression Omnibus (www.ncbi.nlm.nih.gov/geo) with accession number
GSE20198.
Results
IFN-a–induced IFNG gene expression peaks at 6 h of
stimulation
Because the induction of IFNG gene expression by type I IFNs has
been controversial, we were interested in studying how potent
human leukocyte IFN-a is in inducing IFNG transcription in hu-
man umbilical cord blood CD4+ T cells. CD4+ cells, purified using
magnetic selection, were activated with immobilized anti-CD3
and soluble anti-CD28 and cultured in the presence or absence of
100 U/ml IFN-a. In addition, 3 mg/ml neutralizing Ab against
IFN-g was used to inhibit the induction of IFNG gene by autocrine
IFN-g production. Anti–IFN-g (9 mg/ml) has previously been
shown to effectively block IFNGR-induced T-bet expression and
STAT1 phosphorylation in human CD4+ T cells (28). The 3 mg/ml
anti–IFN-g used in this study was also effective in blocking T-bet
induction after 24 h of cell culture in Th1-inducing conditions
(Supplemental Fig. 1). Cells were harvested for quantitative real-
time RT-PCR analysis of IFNG mRNA at the time points of 0, 6,
12, 24, and 48 h. Although anti-CD3/anti-CD28 activation was
a potent inducer of IFNG transcription, IFN-a receptor signaling
greatly enhanced the gene induction, which peaked first at 6 h, was
diminished at 12 h, and induced again at 48 h poststimulation (Fig.
1). The expression peak at 6 h was concordant with the finding
that IFN-a was able to induce only transient STAT4 phosphory-
lation (21).
Microarray studies revealed a set of genes regulated in a similar
manner by IL-12, IL-18, and IFN-a
To identify which genes are regulated in a similar fashion by IFN-a,
IL-12, and the combination of IL-12 and IL-18, microarray studies
were conducted using HG-U133A GeneChip arrays. Human um-
bilical cord blood CD4+ cells were cultured as described in Ma-
terials and Methods, and total RNA was isolated from cells
harvested at different time points. During the first hours of cell
culture, few changes in gene expression can be observed in the
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presence of IL-12 (29) due to the absence of IL12Rb2 on the cell
surface of naive Thp cells. Accordingly, the time point of 48 h was
chosen for studies on the effect of IL-12 and IL-12 plus IL-18 on
gene expression. However, IFN-a signaling is fully functional
already in naive Thp cells and, thus, time points of 2, 6, and 48 h
were chosen for IFN-a–treated samples.
When the IL-12 plus IL-18–induced gene expression changes
were directly compared with those induced by IL-12 (anti-CD3/
anti-CD28 activation plus IL-12 plus IL-18 versus anti-CD3/anti-
CD28 activation plus IL-12), no reproducible changes between
two independent analyses were observed using an SLR cutoff
level of 21 $ SLR $ 1 (i.e., a 2-fold change). However, IL-18
seemed to function as an enhancer of the effects caused by IL-12.
In general, it was observed that most of the genes regulated by the
combination of IL-12 and IL-18 behaved similarly. The response
was only less pronounced than that resulting from IL-12 treatment
alone. Activation of cells with a combination of IL-12 and IL-18
caused the expression of 50 genes to change significantly and
reproducibly when compared with activation only. The data are
provided as supplemental data (Supplemental Table I).
IFN-a induced significant changes in the expression of 172
genes (21 $ SLR $ 1) in at least two of the three time points
studied. The expression of 66 of these changed 4-fold or more, and
among these, there were several genes known to be regulated by
IFN-a, as well as genes previously unknown to be targets of IFN-
a receptor signaling. These data are provided as supplemental data
(Supplemental Table II).
We were most interested in elucidating which genes are regu-
lated in a similar manner by IFN-a, IL-12, and the combination of
IL-12 plus IL-18. We hypothesized that such genes could play an
important role in the polarization of Thp cells along the Th1
lineage. Direct comparisons between the sets of genes that were
found to be regulated in response to IFN-a with the genes regu-
lated by the combination of IL-12 and IL-18 revealed that the
expression patterns of 26 genes were similar. These genes are
presented in Fig. 2 and Supplemental Table III.
LAIR2, SOCS2, andAQP3were downregulated in response to IL-
12, IL-18, and IFN-a receptor signaling and have previously been
associated with Th1/Th2 differentiation (30, 31). CECR1 was also
downregulated in response to IL-12, IL-12 plus IL-18, and IFN-a
and to our knowledge has not previously been associated with Th
functions. Genes that were upregulated in response to IL-12, IL-12
plus IL-18, and IFN-a treatment and previously known to be dif-
ferentially regulated in Th1/Th2 cells included NFIL3, LIF, NKG7,
IL18RAP, 1L12RB2,GZMB, IFNG, GZMH, ADAM19, BCL6, ATF3
GIMAP4, SLC2A3, FOSL2, ZBED2, CTH, and TBX21 (28–30, 32–
40, 41). Genes upregulated and novel in this context were
FLJ12377, GNA15, SERPINB1, DDIT4, and ENPP2.
ATF3 protein is differentially expressed in Th1 and Th2 cells
ATF3 was chosen for further studies because its function in human
Th1 and Th2 differentiation has previously not been examined.
Western blot analysis showed that although ATF3 protein was vir-
tually absent in naive cord blood CD4+ Thp cells, its expression was
rapidly induced after 2 h of TCR activation with anti-CD3 and anti-
CD28mAbs (data not shown). Inducing Th1 polarization with IFN-
a, IL-12, or with IL-12 plus IL-18 further upregulated ATF3 protein
expression, whereas addition of IL-4 downregulated the ATF3
protein expression. This differential regulation of ATF3 protein
became detectable after 12 h of culture and was prominent at 24 h
and 48 h (Fig. 3). The presence of neutralizing anti–IFN-g in the
FIGURE 1. IFN-a–induced IFNG expression peaks at 6 h. Human cord
blood CD4+ T cells were activated with anti-CD3/anti-CD28 (act) in the
presence/absence of human leukocyte IFN-a. Neutralizing anti–IFN-g was
added to both cultures. IFNG gene expression was studied using quanti-
tative real-time RT-PCR. Results were normalized against the reference
gene EEF1A1 and shown as fold difference versus naive Thp cells. Data
are averages from three independent cell cultures. Statistical significance
was determined using Student t test.
FIGURE 2. Twenty-six genes were similarly regulated by IFN-a and the
combination of IL-12 plus IL-18. Human CD4+ cells were activated with
anti-CD3 and anti-CD28 Abs and induced to differentiate with IL-12 plus
IL-18 or IFN-a. Cells treated with IL-12 plus IL-18 were harvested after
48 h and cells treated with IFN-a after 2, 6, or 48 h. The genes regulated in
response to IFN-a treatment at different time points were directly com-
pared with those regulated by IL-12 plus IL-18 after 48 h. Genes showing
similar regulation in response to the different treatments were selected for
further examination. The Venn diagrams show how the genes with similar
expression patterns were regulated by IFN-a during the time-scale studied.
FIGURE 3. ATF3 protein is differentially expressed during the early
stages of Th1 or Th2 cell polarization. Human cord blood CD4+ T cells
were cultured under the conditions indicated for 0, 24, or 48 h. Proteins
were separated on a standard SDS-PAGE gel, transferred to nitrocellulose
membrane, and blotted with rabbit anti-ATF3. b-actin expression was used
as a loading control. Data are representative of four independent analyses.
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culture media demonstrated that the observed regulation of ATF3
expression was not dependent on autocrine IFN-g production.
ATF3 is a positive regulator of IFN-g production and T-bet and
JUN expression
To study the effects of ATF3 overexpression on Th1 differentiation,
human peripheral blood CD4+ T cells were transiently transfected
either with pATF3-IRES2-H-2Kk vector or with an empty vector,
pIRES2-H-2Kk. Dead and apoptotic cells were removed, after
which the cells expressing the H-2Kk selection marker were sorted
with magnetic beads. Overexpression of ATF3 protein was detected
by Western blotting and was shown to be dependent on the amount
of pATF3-IRES2-H-2Kk used for nucleofections (Supplemental
Fig. 2). For differentiation studies, the cells were cultured in Th1-
promoting conditions (i.e., in the presence of anti-CD3/anti-CD28
and IL-12) for 7 d. The ability of the cells to produce IFN-g after
restimulation with PMA plus ionomycin was studied using in-
tracellular cytokine staining and flow cytometry (Fig. 4A). The
percentage of IFN-g–positive cells, especially cells that stained
highly positive for IFN-g, was higher in the cell population ex-
pressing ectopic ATF3 than in the mock-transfected cells. The two
distinct IFN-g–positive cell populations are typically detected by
intracellular staining and flow cytometry (21, 42, 43) and can be
considered as IFN-g+ (high) and IFN-g+ (low) cell populations.
To confirm the role of ATF3 in IFN-g expression by an alter-
native approach, specific siRNA oligonucleotides targeting ATF3
mRNAwere designed. Scrambled sequence was used as a control.
Human cord blood CD4+ cells were transiently transfected with
the siRNA oligonucleotides and subsequently induced to differ-
entiate toward Th1 by anti-CD3/anti-CD28 activation and IL-12.
FIGURE 4. ATF3 promotes Th1 differen-
tiation by inducing IFN-g production. A, The
ATF3 gene was introduced into peripheral
blood CD4+ cells in pATF3-IRES2-H-2Kk
vector by nucleofection. Cells nucleofected
with an empty vector pIRES2-H-2Kk were
used as controls. Dead cells were removed,
and H-2Kk–positive transfected cells were
sorted by magnetic beads. Cells were cultured
for 7 d in Th1-polarizing conditions, after
which half of the cells were restimulated with
PMA plus ionomycin, whereas the other half
was left unstimulated. Cells were stained for
intracellular IFN-g production and analyzed
with a flow cytometer. The values represent
the percentage of cells stained positive for
IFN-g production and the geometrical mean
of fluorescence intensity. Data are represen-
tative of three independent analyses. B–D,
Human cord blood CD4+ T cells were tran-
siently transfected with siRNA oligonucleo-
tides targeted against ATF3. Scrambled
sequence was used as a control. Sub-
sequently, the cells were activated with anti-
CD3/anti-CD28 and induced to differentiate
toward Th1 in the presence of IL-12 for 7 d.
B, ATF3 knockdown as well as T-bet and
JUN expression was assayed by Western
blotting after 0, 24, and 48 h of stimulation.
Data are representative of three to five in-
dividual experiments and obtained using
ATF3-siRNA-new2. C, The relative ATF3, T-
bet, and JUN protein expression was quanti-
fied from three to five individual cultures, and
the figure shows the average values with error
bars indicating the SD. D, Supernatants were
collected 24 h poststimulation for IFN-g as-
say, and reduction in the amount of secreted
INF-g was observed in five out of seven in-
dependent experiments. The averages of
these five are shown in the figure. Cells cul-
tured for 7 d were restimulated with PMA
and ionomycin for 24 h, after which the su-
pernatants were harvested for IFN-g assay.
The figure shows average reduction of IFN-g
secretion from six out of eight independent
experiments in which the reduction was ob-
served. Error bars indicate SD. N.D., not
detected.
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Because ATF3 expression was not detectable by Western blotting
in undifferentiated cells, the efficacy of the knockdown was ex-
amined from stimulated cells. The residual expression of ATF3
protein varied depending on the oligonucleotide used, but was on
average 57% and 46% after 24 h and 48 h of differentiation, re-
spectively (Fig. 4B, 4C).
The effect of ATF3 knockdown on IFN-g production was
measured from the supernatant by cytokine bead assay after 24 h
of stimulation as well as after restimulation of cells cultured for
7 d (Fig. 4D). These experiments verified the role of ATF3 as
a positive regulator of IFN-g expression, because the selective
knockdown of ATF3 resulted in reduced amounts of IFN-g pro-
duction. Consistently, the knockdown of ATF3 also resulted in
diminished amounts of T-bet expression (Fig. 4B, 4C). Most
likely, this was due to the decreased level of IFN-g. However, it is
also possible that ATF3 regulated T-bet expression directly by
binding to its promoter or via other signaling routes.
JUN is a known positive regulator of ATF3 transcription (44–47),
and there is also implication that ATF3 may control JUN ex-
pression (48). Furthermore, a recent report described ATF2 as
a positive regulator of JUN expression in human T cells (49).
Thus, we examined the effect of ATF3 knockdown on JUN ex-
pression also and discovered that the ATF3 knockdown resulted in
decreased expression of JUN (Fig. 4B, 4C). Importantly, JUN
expression was not affected by ATF3 knockdown at the time of
activation (0 h sample), thus indicating that JUN was not an off-
target of ATF3 siRNA.
ATF3 and JUN dimerize upon IL-12 stimulation
ATF3 homodimers are known to act as transcriptional repressors
(50), but heterodimers ATF3/JUN or ATF3/JUND possess tran-
scriptional activator function (51, 52). Our results clearly in-
dicated that ATF3 was a positive regulator of IFNG transcription.
This allowed us to hypothesize that to form an activating complex,
ATF3 dimerizes with JUN, a transcription factor induced by Th1
differentiation (Supplemental Table I). To test the hypothesis, we
conducted coimmunoprecipitation assays of nuclear extracts of
cord blood CD4+ cells induced to differentiate toward Th1 and
Th2 lineages for 48 h. Both anti-ATF3 and anti-JUN Abs were
used for immunoprecipitation, and the protein/Ab complexes were
isolated using protein G-Sepharose beads. Proteins were eluted to
SDS sample buffer and resolved by SDS-PAGE. Immunoblotting
assays showed (Fig. 5A) that endogenous ATF3 and JUN coim-
munoprecipitated in cells induced to polarize to Th1 direction but
not in cells polarized to Th2 direction.
To test the hypothesis further, we cotransfected pJUN-IRES2-H-
2Kk and pATF3-IRES2-H-2Kk vectors into Jurkat cells to study
the resulting induction of IFNG transcription by quantitative real-
time RT-PCR. Posttransfection, the cells were rested o/n and ac-
tivated with PMA/PHA. The cells were harvested after 24 h of
activation. Real-time RT-PCR analysis showed (Fig. 5B) that al-
though both JUN and ATF3 transfection enhanced IFNG tran-
scription compared with the empty vector, the induction induced
by cotransfection was greater than that induced by either of the
transgenes alone.
ATF3 and JUN bind and transactivate human IFNG promoter
ChIP assays were performed to study the recruitment of ATF3 and
JUN to the cis regulatory elements of the IFNG promoter. Abs
specific for ATF3 and a JUN-specific antiserum was used. Primers
were designed to amplify both the proximal and distal elements of
the human IFNG promoter. Three different regions were studied:
from 21763 to 21084, from 21147 to 2293, and from 2458 to
+216. The ChIP assays were performed on nuclear fractions of
human umbilical cord blood CD4+ T cells induced to differentiate
toward Th0, Th1, and Th2 for 9 h as well as undifferentiated Thp
cells to study the recruitment of ATF3 and JUN to the IFNG pro-
moter in the early stages of Th differentiation. Reproducible binding
of both ATF3 and JUN was observed with a primer pair that
amplified a 855-bp fragment of the distal promoter (from21147 to
2293) (Fig. 6A). The band intensities were quantified with a den-
sitometer, and the data from anti-ATF3– and anti-JUN–precipitated
sampleswere normalized to control IgG.The data demonstrated that
the recruitment of bothATF3 and JUN to this regionwas specific for
Th1-promoting conditions and statistically significant (p = 0.004
and p = 0.006, respectively) (Fig. 6B). Some binding of ATF3 and
JUN to the other regions (from21763 to21084 and from2458 to
+216) was also detected, but this binding was neither reproducible
nor specific for Th1-inducing conditions (data not shown).
FIGURE 5. ATF3/JUN dimer is formed in CD4+ cells induced to differ-
entiate along Th1 lineage and induces IFNG expression in Jurkat cells. A,
Human cord blood CD4+ T cells were activated using anti-CD3 and anti-
CD28 (act) and induced to polarize toward Th1 lineage by IL-12 or toward
Th2 lineage by IL-4. After 48 h, the cells were harvested and nuclear frac-
tions were prepared. Coimmunoprecipitations were performed using 1.5 mg
anti-ATF3 Ab or 10 ml anti-JUN antiserum. A total of 1.5 mg anti-RANKL
Ab was used as a control. One sample was treated with no Abs. Im-
munoprecipitated protein complexes were separated by SDS-PAGE, trans-
ferred to nitrocellulose membrane, and blotted with anti-JUN mAb. As
controls, T-bet and GATA3 were detected from total cell lysates (10% of
input) to demonstrate that the cells have been induced to polarize properly.
The results showed that JUN coimmunoprecipitated with ATF3 in cells in-
duced to differentiate toward the Th1 lineage but not in cells induced to Th2.
Themembranewas also blottedwith anti-ATF3, but the resulting bandswere
masked by unspecific signals resulting from protein G (data not shown). No
mAbs forATF3were available at the time of study. Data are representative of
three individual experiments. B, Jurkat cells were transfected with indicated
plasmids and rested for 24 h. The cells were activated with PMA/PHA,
harvested after 24 h, and H-2Kk–positive cells were selected using magnetic
beads. Quantitative real-time RT-PCR analysis showed that although ectopic
expression of either ATF3 or JUN increased IFNG mRNA expression, co-
transfection of both transgenes further increased IFNG expression. Data are
the average of five individual experiments. Statistical significance was
evaluated with Student t test. Error bars indicate SEM.
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Although ATF3 and JUN were able to form a protein complex in
Th1-inducing conditions, and they both were recruited to the IFNG
promoter, the data do not enable us to make conclusions about the
possibility that the two factors may bind in a cooperative fashion.
To further study the potential of ATF3 and JUN to bind and
transactivate the IFNG promoter, we designed and exploited lu-
ciferase reporter assays. As the ChIP analysis showed binding of
both ATF3 and JUN on promoter areas 1.1 kb upstream of the
IFNG gene transcription initiation site, the luciferase assays were
designed to cover the promoter from 21147 to +38 (Fig. 7). The
promoter fragments were cloned in front of the luciferase gene
(luc2) (Fig. 7A), and the IFNG promoter constructs were co-
transfected to Jurkat Jtag cells with either ATF3 or JUN over-
expression vectors or both of them. The resulting luminescence
signals were compared with the signal obtained by cotransfection
of the IFNG promoter constructs with an empty vector (Fig. 7B).
When ATF3 was cotransfected alone with any of the IFNG pro-
moter constructs, the luciferase activity was increased only by 1.2-
to 1.3-fold, which may indicate that ATF3 is not able to bind the
promoter alone. JUN overexpression caused a .10-fold increase
in the luciferase signal. The increase in luciferase activity was
expected, because Jurkat cells express endogenously both ATF3
and JUN (data not shown) as well as other AP-1 transcription
factors that are able to form heterodimers with ATF3 and JUN.
Most importantly, cotransfecting both ATF3 and JUN over-
expression vectors with the promoter constructs resulted in all
cases in higher luciferase activity than transfecting JUN alone.
When evaluated with the Student t test, these differences were also
statistically significant (p, 0.02) in all cases but one (pIFNG940-
GL4.10, p = 0.14). The results also showed that most likely there
is more than one functional binding site for ATF3 and JUN in the
IFNG promoter because the average signal obtained with co-
transfection of the longest promoter construct with ATF3 and JUN
was 1.4-fold when compared with the average signal obtained
with the shortest promoter construct (p = 0.025).
ATF3 and JUN binding sites on IFNG promoter were analyzed,
and five putative sites were found: an AP-1 site from 2978 to
2968 (59-tcctgcctcagccct-39, del1), an AP-1 site from 2320 to
2311 (59-agagtcaaca-39, del2), a JUN site from 2200 to 2191
(59-gtctgtctcat-39, del3), an ATF site from 262 to 252 (59-aaa-
tacgtaat-39, del4), and a CREB site from 2256 to 2249 (59-
tgaagtaaa-39, del5) (Fig. 7A). Deletion mutations were made to
the pIFNG1147-GL4.10 plasmid to study the functionality of
these sites. As indicated above, the putative binding sites are in
italics, and the deleted regions are underlined. Each of the mutated
constructs had one intact putative binding site and deletions in the
four other sites. One construct had deletions in all five putative
sites. The mutation constructs were cotransfected to Jtag cells with
ATF3 and JUN plasmid constructs as above. The results (Fig. 7C,
7D) indicated that deletion of all five sites was needed to abolish
binding of ATF3 to the promoter, and, thus, the binding was
shown to be cooperative. However, JUN was still able to bind and
transactivate transcription, suggesting that additional binding sites
exist for other JUN complexes. Also, when all five binding sites
were deleted, ATF3 inhibited JUN binding, possibly by seques-
tering JUN away from the promoter.
Discussion
To find potential new players involved in the initiation of human Th1
differentiation, we used transcriptomics and identified a panel of 26
genes that are regulated in a similar manner by IL-12, IFN-a, and the
combination of IL-12plus IL-18 inhumanumbilical cordbloodCD4+
cells. The set of the genes regulated by Th1-inducing cytokines in-
cluded genes known and new in this context. ATF3 was significantly
upregulated by all the cytokines studied. Differential expression of
ATF3 in human Th1-inducing conditions has previously not been
reported. The expression of ATF3 was also increased at the protein
level in Th1-promoting conditions. Furthermore, its expression was
found to be downregulated by IL-4, a Th2-promoting cytokine.
ATF3 is a member of the mammalian ATF/CREB protein family
of transcription factors. ATF3 is a stress-inducible gene. However,
little is known about the signaling pathways involved in the in-
duction of ATF3 as well as the role of ATF3 in stress responses.
Previous work from our group demonstrated that ATF3 is regu-
lated via the IL-4R-induced STAT6 signaling pathway in murine
CD4+ cells and that its transcript is more abundant in Th2 cells
FIGURE 6. ATF3 and JUN are recruited to the IFNG
promoter in Th1-promoting conditions. Umbilical cord
blood CD4+ T cells were induced to differentiate to-
ward Th0, Th1, or Th2 in the presence of anti–IFN-g
for 9 h. ChIP was performed with both anti-ATF3 and
JUN antiserum. Reproducible binding of ATF3 and
JUN was detected in Th1- promoting conditions. PCR
was performed using primers amplifying the IFNG
promoter from 21147 to 2293. A, A representative
result from at least three independent experiments is
shown. B, The band intensities were quantified with
a densitometer, and the data from anti-ATF3 and anti-
JUN precipitated samples were normalized against
control IgG. Error bars indicate SEM. ppp , 0.01. act,
anti-CD3/anti-CD28 activation.
4996 ATF3 REGULATES IFNG EXPRESSION
 o
n
 M
ay 26, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
than in Th1 cells (32). ATF3 gene expression has also been re-
ported to be induced by both IFN-g and IL-4 in murine macro-
phages (53), by pegylated IFN-a in PBMCs (54) and by IL-12 in
murine NK cells (55). A study using systems biology approaches
identified ATF3 as a negative regulator of TLR-stimulated murine
macrophage responses (56). In that study, ATF3, as a part of
a transcriptional complex also containing members of the NF-kB
transcription factors, was shown to act as a transcriptional re-
pressor of Il6 and Il12b upon macrophage activation. Furthermore,
Whitmore et al. (57) showed that ATF3 gene expression was up-
regulated by TLR signaling in mouse and human APCs and that
ATF3 acted as a negative regulator of IL-12 and IL-6 production
by macrophages. ATF3 has also been shown to be a negative
regulator of IFNG gene expression in mouse NK cells (55). Re-
cently, the role of ATF3 was studied in a mouse asthma model
(58). Gilchrist et al. (58) showed that ATF3 was induced in the
lungs of OVA-challenged mice and that ATF3-deficient mice
showed more severe symptoms of asthma than wild-type mice.
Consistent with our previous studies in mouse cells (32), they
demonstrated that the expression of ATF3 in CD4+ mouse T cells
was upregulated by Th2 cytokines but not by Th1 cytokines. They
further showed that ATF3 bound the Th2 cytokine locus in the
chromatin of mouse Th2 cells and that ATF3 inhibited IL-4, IL-5,
and IL-13 secretion.
Importantly, there are no previous data on ATF3 expression or
function in human CD4+ T cells in response to Th1/Th2-inducing
cytokines. We demonstrated in this study that, in contrast to mouse
CD4+ T cells, in human CD4+ cells, ATF3 protein levels were
clearly higher in cells induced to differentiate along a Th1 lineage
than along a Th2 lineage and that ATF3 positively regulated
FIGURE 7. ATF3 and JUN transactivate the IFNG promoter. A, Up to ∼1.1 kb fragment of the human IFNG promoter was cloned in front of the luc2
gene in pGL4.10 vector. Sequence analysis revealed five putative ATF3/JUN binding sites, which are marked with arrows. B, The IFNG promoter constructs
were cotransfected to Jurkat Jtag cells with either pATF3-IRES2-H-2Kk or pJUN-IRES2-H-2Kk or both. The cells were activated with PMA plus PHA the
next day, and the luminescence signals were read 24 h postactivation. The figure shows average values from two to seven independent cultures. C, The
mutated IFNG promoter constructs were cotransfected to Jurkat Jtag cells with pATF3-IRES2-H-2Kk or pJUN-IRES2-H-2Kk or both. Each promoter
construct had only one intact binding site left. One construct had deletions in all putative binding sites. D, Deletion of all five putative ATF3/JUN binding
sites abolished the ability of ATF3 to transactivate the IFNG promoter. Statistical significance was determined with Student t test. Error bars indicate SEM.
pp , 0.05; ppp , 0.01.
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human IFNG gene expression and Th1 differentiation. Thus, using
a different mechanism, ATF3 plays a similar role in human and
mouse CD4+ Th cell differentiation: to drive the Th1/Th2 balance
toward the Th1 lineage.
AP-1 transcription factors consist of JUN and FOS family
proteins that can form homo- or heterodimers not only with each
other, but also with proteins of the ATF/CREB or MAF protein
families (59). AP-1 transcription factors are induced upon acti-
vation of naive Thp cells, and the different complexes have se-
lective functions in the regulation of effector Th cell
differentiation (60, 61). In general, the ATF3 homodimer is known
to act as a repressor of transcription. However, the function of
ATF3 is dependent on its binding partner because selective het-
erodimers ATF3/JUN and ATF3/JUND have been shown to result
in transcriptional activation (51, 52). JUN is a known positive
regulator of IFNG gene expression (62, 63). JUN is able to form
heterodimers with ATF2 that have been shown to bind and
transactivate the IFNG promoter (49, 62, 63). As JUN was also
upregulated by IL-12 and IL-12 plus IL-18 in our microarray
analysis, we hypothesized that ATF3 may form an activating
complex with JUN and thereby induce IFN-g production. To study
this, we performed coimmunoprecipitation assays of primary hu-
man CD4+ T cells induced to differentiate along Th1 or Th2
lineages and showed that ATF3/JUN complexes were formed in
Th1-inducing conditions. ATF3 and JUN showed an additive ef-
fect on IFNG gene expression when transfected to Jurkat cells as
compared with transfecting with either one of them alone. Re-
cruitment of both ATF3 and JUN to a human IFNG promoter was
verified by ChIP analysis, which showed specific binding of both
in Th1-promoting conditions. Luciferase reporter assays further
showed that both ATF3 and JUN were able to transactivate the
IFNG promoter, and the assays also suggested that multiple
binding sites for ATF3 and JUN exist. Sequence analysis revealed
five putative binding sites, and their functionality was studied by
making deletion mutations of the sites. The recruitment of ATF3
to the promoter was cooperative, as the assays showed that all five
sites needed to be deleted to abolish ATF3 binding. However,
when all putative sites were deleted, JUN was still able to bind and
transactivate the promoter. Highest luciferase activity was ob-
tained when ATF3 and JUN were cotransfected with the promoter
constructs. This, and the finding that ATF3 inhibited binding of
JUN when all five putative binding sites were deleted, suggests
complex formation. Additional studies, such as sequential ChIP,
could be performed to verify ATF3 and JUN corecruitment to the
IFNG locus.
We also aimed to clarify the role of IFN-a in human Th1 dif-
ferentiation. Our results on transient IFNG gene induction by IFN-
a in cord blood CD4+ cells (Fig. 1) are in concordance with the
finding that IFN-a is able to only transiently phosphorylate STAT4
(21, 64). Furthermore, with flow cytometric analysis, we cannot
detect any increase in the number of IFN-g–producing cord blood
CD4+ cells following activation and IFN-a treatment for either
48 h (28) or 7 d (data not shown) when compared with activation
only. Thus, IFN-a was not able to drive Th1 differentiation.
Significantly, however, we show in this study that IFN-a regulates
a number of genes in a similarmanner to IL-12 or the combination of
IL-12 plus IL-18. Among these are also genes undoubtedly involved
in Th1 differentiation, namely TBX21, IL12RB2, IL18RAP, and
IFNG, which all were significantly upregulated. Based on our re-
sults, we propose the following model whereby IFN-a promotes
human Th1 differentiation. IFN-a, IL-12, and IL-18 are produced
by activated macrophages during microbial infections. Our findings
suggest that by increasing the expression of IL12RB2, IL18RAP,
TBX21, and IFNG, IFN-a increases the ability of Thp cells to re-
spond to IL-12 and IL-18. This in turn efficiently drives Thp cells
toward the Th1 lineage.
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